Catriana C Nations1,2, Giulia Pavani2, Deborah L French2,3, Paul Gadue2,3. 1. Department of Cell and Molecular Biology, University of Pennsylvania Perelman School of Medicine. 2. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia. 3. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Megakaryocytes are rare hematopoietic cells that play an instrumental role in hemostasis, and other important biological processes such as immunity and wound healing. With the advent of cell reprogramming technologies and advances in differentiation protocols, it is now possible to obtain megakaryocytes from any pluripotent stem cell (PSC) via hematopoietic induction. Here, we review recent advances in PSC-derived megakaryocyte (iMK) technology, focusing on platform validation, disease modeling and current limitations. RECENT FINDINGS: A comprehensive study confirmed that iMK can recapitulate many transcriptional and functional aspects of megakaryocyte and platelet biology, including variables associated with complex genetic traits such as sex and race. These findings were corroborated by several pathological models in which iMKs revealed molecular mechanisms behind inherited platelet disorders and assessed the efficacy of novel pharmacological interventions. However, current differentiation protocols generate primarily embryonic iMK, limiting the clinical and translational potential of this system. SUMMARY: iMK are strong candidates to model pathologic mutations involved in platelet defects and develop innovative therapeutic strategies. Future efforts on generating definitive hematopoietic progenitors would improve current platelet generation protocols and expand our capacity to model neonatal and adult megakaryocyte disorders.
PURPOSE OF REVIEW: Megakaryocytes are rare hematopoietic cells that play an instrumental role in hemostasis, and other important biological processes such as immunity and wound healing. With the advent of cell reprogramming technologies and advances in differentiation protocols, it is now possible to obtain megakaryocytes from any pluripotent stem cell (PSC) via hematopoietic induction. Here, we review recent advances in PSC-derived megakaryocyte (iMK) technology, focusing on platform validation, disease modeling and current limitations. RECENT FINDINGS: A comprehensive study confirmed that iMK can recapitulate many transcriptional and functional aspects of megakaryocyte and platelet biology, including variables associated with complex genetic traits such as sex and race. These findings were corroborated by several pathological models in which iMKs revealed molecular mechanisms behind inherited platelet disorders and assessed the efficacy of novel pharmacological interventions. However, current differentiation protocols generate primarily embryonic iMK, limiting the clinical and translational potential of this system. SUMMARY: iMK are strong candidates to model pathologic mutations involved in platelet defects and develop innovative therapeutic strategies. Future efforts on generating definitive hematopoietic progenitors would improve current platelet generation protocols and expand our capacity to model neonatal and adult megakaryocyte disorders.
Authors: Jon P Connelly; Erika M Kwon; Yongxing Gao; Niraj S Trivedi; Abdel G Elkahloun; Marshall S Horwitz; Linzhao Cheng; P Paul Liu Journal: Blood Date: 2014-09-18 Impact factor: 22.113
Authors: Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith Journal: Blood Date: 2011-08-17 Impact factor: 22.113
Authors: Kathleen E McGrath; Jenna M Frame; Katherine H Fegan; James R Bowen; Simon J Conway; Seana C Catherman; Paul D Kingsley; Anne D Koniski; James Palis Journal: Cell Rep Date: 2015-06-18 Impact factor: 9.423
Authors: M Sakurai; H Kunimoto; N Watanabe; Y Fukuchi; S Yuasa; S Yamazaki; T Nishimura; K Sadahira; K Fukuda; H Okano; H Nakauchi; Y Morita; I Matsumura; K Kudo; E Ito; Y Ebihara; K Tsuji; Y Harada; H Harada; S Okamoto; H Nakajima Journal: Leukemia Date: 2014-04-15 Impact factor: 11.528
Authors: Dorin-Mirel Popescu; Rachel A Botting; Emily Stephenson; Kile Green; Simone Webb; Laura Jardine; Emily F Calderbank; Krzysztof Polanski; Issac Goh; Mirjana Efremova; Meghan Acres; Daniel Maunder; Peter Vegh; Yorick Gitton; Jong-Eun Park; Roser Vento-Tormo; Zhichao Miao; David Dixon; Rachel Rowell; David McDonald; James Fletcher; Elizabeth Poyner; Gary Reynolds; Michael Mather; Corina Moldovan; Lira Mamanova; Frankie Greig; Matthew D Young; Kerstin B Meyer; Steven Lisgo; Jaume Bacardit; Andrew Fuller; Ben Millar; Barbara Innes; Susan Lindsay; Michael J T Stubbington; Monika S Kowalczyk; Bo Li; Orr Ashenberg; Marcin Tabaka; Danielle Dionne; Timothy L Tickle; Michal Slyper; Orit Rozenblatt-Rosen; Andrew Filby; Peter Carey; Alexandra-Chloé Villani; Anindita Roy; Aviv Regev; Alain Chédotal; Irene Roberts; Berthold Göttgens; Sam Behjati; Elisa Laurenti; Sarah A Teichmann; Muzlifah Haniffa Journal: Nature Date: 2019-10-09 Impact factor: 69.504
Authors: Cornelis A Albers; Dirk S Paul; Harald Schulze; Kathleen Freson; Jonathan C Stephens; Peter A Smethurst; Jennifer D Jolley; Ana Cvejic; Myrto Kostadima; Paul Bertone; Martijn H Breuning; Najet Debili; Panos Deloukas; Rémi Favier; Janine Fiedler; Catherine M Hobbs; Ni Huang; Matthew E Hurles; Graham Kiddle; Ingrid Krapels; Paquita Nurden; Claudia A L Ruivenkamp; Jennifer G Sambrook; Kenneth Smith; Derek L Stemple; Gabriele Strauss; Chantal Thys; Chris van Geet; Ruth Newbury-Ecob; Willem H Ouwehand; Cedric Ghevaert Journal: Nat Genet Date: 2012-02-26 Impact factor: 38.330